Company intelligence / Profile preview

Biotar

Rehovot, Israel

Ownership: Private
Development stage: Other

Overview

Biotar was an Israeli biotechnology company focused on the development of novel antibiotics and therapeutic agents targeting the bacterial ribosome. The company's primary research centered on overcoming antibiotic resistance by designing molecules that interact with specific ribosomal sites to inhibit protein synthesis. Their lead programs were aimed at treating chronic respiratory infections, particularly in patients with cystic fibrosis. Although the company showed early promise in pre-clinical models, it is no longer active in the commercial biotech landscape.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small moleculeDrug delivery
Industry: Biotech

Beyond the preview

Go deeper on Biotar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotar.

Explore the full profile